Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

NCT01607957 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT01607957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01607957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 17, 2012
Completion date
May 23, 2016
Enrollment
800 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer